NCT04590326: An ongoing trial by Regeneron Pharmaceuticals
This trial is ongoing. It must report results 2 years, 3 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT04590326 |
|---|---|
| Title | A Phase 1/2 Study of REGN5668 (MUC16xCD28, a Costimulatory Bispecific Antibody) Administered in Combination With Other Agents in MUC16 + Malignancies |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Dec. 8, 2020 |
| Completion date | March 25, 2027 |
| Required reporting date | March 24, 2028, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |